JP2013530237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530237A5 JP2013530237A5 JP2013518685A JP2013518685A JP2013530237A5 JP 2013530237 A5 JP2013530237 A5 JP 2013530237A5 JP 2013518685 A JP2013518685 A JP 2013518685A JP 2013518685 A JP2013518685 A JP 2013518685A JP 2013530237 A5 JP2013530237 A5 JP 2013530237A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- salt
- compound
- following groups
- following
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- -1 N-pyrrolidinyl Chemical group 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 102000000568 rho-Associated Kinases Human genes 0.000 claims 2
- 108010041788 rho-Associated Kinases Proteins 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 0 *c1ccc(CCN(C2)*#C)c2c1 Chemical compound *c1ccc(CCN(C2)*#C)c2c1 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36203610P | 2010-07-07 | 2010-07-07 | |
| US61/362,036 | 2010-07-07 | ||
| PCT/US2011/042507 WO2012006202A1 (en) | 2010-07-07 | 2011-06-30 | Rho kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530237A JP2013530237A (ja) | 2013-07-25 |
| JP2013530237A5 true JP2013530237A5 (enExample) | 2014-08-14 |
| JP5799479B2 JP5799479B2 (ja) | 2015-10-28 |
Family
ID=44514975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518685A Active JP5799479B2 (ja) | 2010-07-07 | 2011-06-30 | Ｒｈｏキナーゼインヒビター |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9079880B2 (enExample) |
| EP (1) | EP2590942B1 (enExample) |
| JP (1) | JP5799479B2 (enExample) |
| WO (1) | WO2012006202A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| EP2630144B1 (en) | 2010-10-19 | 2016-09-07 | Boehringer Ingelheim International GmbH | Rho kinase inhibitors |
| WO2014055996A2 (en) * | 2012-10-05 | 2014-04-10 | Kadmon Corporation, Llc | Rho kinase inhibitors |
| TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物 |
| EP2961746B1 (en) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| US10112939B2 (en) | 2014-08-21 | 2018-10-30 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| US9353093B2 (en) | 2014-10-07 | 2016-05-31 | Allergan, Inc. | Indole-1-carboxamides as kinase inhibitors |
| US10112929B2 (en) | 2015-03-09 | 2018-10-30 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| US11332470B2 (en) * | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| AU2017351216C1 (en) * | 2016-10-24 | 2021-10-14 | Translational Drug Development, Llc | Amide compounds as kinase inhibitors |
| US10738007B2 (en) | 2016-10-24 | 2020-08-11 | Translation Drug Development, LLC | Amide compounds as kinase inhibitors, compositions and methods of treatment |
| AU2020273376C1 (en) * | 2016-10-24 | 2024-02-29 | Translational Drug Development, Llc | Amide compounds as kinase inhibitors, compositions and methods of treatment |
| GB201705686D0 (en) | 2017-04-07 | 2017-05-24 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| AU2018311976B2 (en) * | 2017-08-04 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Inhibitors of Plasma Kallikrein and uses thereof |
| BR112020005489A2 (pt) | 2017-09-22 | 2020-09-24 | Jubilant Epipad Llc, | composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| CN107903185B (zh) * | 2017-11-08 | 2020-05-26 | 四川大学 | 新型eEF2K抑制剂的制备及应用 |
| IL274762B2 (en) | 2017-11-24 | 2023-10-01 | Jubilant Episcribe Llc | Novel heterocyclic compounds as prmt5 inhibitors |
| EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| JP7490569B2 (ja) * | 2018-04-24 | 2024-05-27 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | キナーゼ阻害剤としてのアミド化合物、組成物および処置方法 |
| US12281308B2 (en) | 2018-08-29 | 2025-04-22 | University Of Massachusetts | Inhibition of protein kinases to treat Friedreich ataxia |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2516384B2 (ja) * | 1987-11-27 | 1996-07-24 | 保土谷化学工業株式会社 | ペンズアミド誘導体 |
| US5210208A (en) | 1990-09-24 | 1993-05-11 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity |
| NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
| JPH11130751A (ja) | 1997-10-30 | 1999-05-18 | Yoshitomi Pharmaceut Ind Ltd | アミド化合物およびそれらの酸付加塩の標識化合物 |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| EP1339668A2 (en) | 2000-11-28 | 2003-09-03 | Guilford Pharmaceuticals Inc. | Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
| DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
| US7199147B2 (en) | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| DE10250743A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| WO2004071448A2 (en) | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
| FR2862965B1 (fr) | 2003-11-27 | 2007-09-07 | Merck Sante Sas | Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides. |
| US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| AU2005305140A1 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Arylalkyl ureas as CB1 antagonists |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| ES2580108T3 (es) | 2005-07-11 | 2016-08-19 | Aerie Pharmaceuticals, Inc | Compuestos de isoquinolina |
| CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| WO2008053319A1 (en) | 2006-10-30 | 2008-05-08 | Pfizer Products Inc. | Amide resorcinol compounds |
| US8012955B2 (en) | 2006-12-28 | 2011-09-06 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| CL2007003874A1 (es) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| WO2008157330A1 (en) | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
| US8445686B2 (en) | 2007-08-27 | 2013-05-21 | Abbvie Inc. | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| US20100227846A1 (en) | 2007-08-30 | 2010-09-09 | Takeda Pharmaceutical Company Limited | Substituted pyrazole derivative |
| JP5544296B2 (ja) | 2007-11-16 | 2014-07-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
| TW200944506A (en) | 2008-03-26 | 2009-11-01 | Takeda Pharmaceutical | Substituted pyrazole derivatives and use thereof |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| EP2630144B1 (en) | 2010-10-19 | 2016-09-07 | Boehringer Ingelheim International GmbH | Rho kinase inhibitors |
-
2011
- 2011-06-29 US US13/171,701 patent/US9079880B2/en active Active
- 2011-06-30 WO PCT/US2011/042507 patent/WO2012006202A1/en not_active Ceased
- 2011-06-30 JP JP2013518685A patent/JP5799479B2/ja active Active
- 2011-06-30 EP EP11730533.4A patent/EP2590942B1/en active Active